公开(公告)号：US06383738B1

公开(公告)日：2002-05-07

申请号：US09206676

申请日：1998-12-07

申请人： Renato Bruni ,  Bernard Roizman

发明人： Renato Bruni ,  Bernard Roizman

IPC分类号： A61K39245

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/00 ,  C12N2710/16622 ,  C12N2710/16643

摘要： The present invention is directed to methods and compositions relating to the treatment of herpes simplex virus infections and the screening of compounds for activity that inhibit or promote viral latency. The previously identified ORF P gene product now has been shown to interact with certain eukaryotic splicing factors and, in a cell infected with a herpesvirus containing a derepressed ORF P gene, ORF P can limit the splicing of at least two viral products. Given this function, it now is possible to screen for inhibitors and inducers of ORF P and, further, provide methods for maintaining and preventing viral latency.

摘要翻译： 本发明涉及涉及治疗单纯疱疹病毒感染和筛选化合物以抑制或促进病毒潜伏期的活性的方法和组合物。 现在已经显示先前鉴定的ORF P基因产物与某些真核剪接因子相互作用，并且在含有去抑制ORF P基因的疱疹病毒感染的细胞中，ORF P可以限制至少两种病毒产物的剪接。 鉴于此功能，现在可以筛选ORF P的抑制剂和诱导剂，并进一步提供维持和预防病毒潜伏期的方法。

公开(公告)号：US5846948A

公开(公告)日：1998-12-08

申请号：US706308

申请日：1996-08-30

申请人： Renato Bruni ,  Bernard Roizman

发明人： Renato Bruni ,  Bernard Roizman

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K39/245 ,  A61K39/395 ,  A61K48/00 ,  A61P31/20 ,  C07K14/035 ,  C07K16/08 ,  C12N15/38 ,  C12P21/08 ,  A01N43/06 ,  C07H21/04 ,  C12Q1/68

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/00 ,  C12N2710/16622 ,  C12N2710/16643

摘要： The present invention is directed to methods and compositions relating to the treatment of herpes simplex virus infections and the screening of compounds for activity that inhibit or promoter viral latency. The previously identified ORF P gene product now has been shown to interact with certain eukaryotic splicing factors and, in a cell infected with a herpesvirus containing a derepressed ORF P gene, ORF P can limit the splicing of at least two viral products. Given this function, it now is possible to screen for inhibitors and inducers of ORF P and, further, provide methods for maintaining and preventing viral latency.

摘要翻译： 本发明涉及涉及治疗单纯疱疹病毒感染和筛选化合物以抑制或启动病毒潜伏期的活性的方法和组合物。 现在已经显示先前鉴定的ORF P基因产物与某些真核剪接因子相互作用，并且在含有去抑制ORF P基因的疱疹病毒感染的细胞中，ORF P可以限制至少两种病毒产物的剪接。 鉴于此功能，现在可以筛选ORF P的抑制剂和诱导剂，并进一步提供维持和预防病毒潜伏期的方法。